CLINICAL STAGE ASSETS

Four investigational immunotherapies targeting a range of types of cancers.

Axalimogene Filolisbac
(AXAL)

Advaxis’ lead Lm Technology™ immunotherapy axalimogene filolisbac (AXAL) targets HPV-associated cancers and is in a Phase 3 clinical trial for high-risk, locally advanced cervical cancer.

LEARN MORE

ADXS-PSA

ADXS-PSA is under investigation for targeting the prostate-specific antigen (PSA) associated with prostate cancer and is in clinical development both as a monotherapy and in combination with immune checkpoint inhibitors for the treatments of metastatic castration-resistant prostate cancer (mCRPC).

LEARN MORE

NEOANTIGEN-DIRECTED THERAPIES

From personalized to off-the-shelf our neoantigen-directed constructs are in leveraging advances in gene sequencing to pursue individualized approaches to cancer therapies.

LEARN MORE

SURVIVOR STORIES

Hear the personal stories of men and women who have fought cancer with axalimogene filolisbac in clinical trials.

LEARN MORE

Partnerships

Advaxis has embraced strategic collaborations with other major biopharmaceutical companies for the development and commercialization of some of its proprietary cancer immunotherapies. In addition, Advaxis is developing numerous distinct proprietary immunotherapies directly or in partnership with recognized cancer centers of excellence and with support from advocacy foundations.

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases and Advaxis breaking news.

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.